Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.52 |
| ▸ | CNR1 | P21554 | 9/20 | 0.50 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | CTRC | Q99895 | 1/20 | 0.44 |
| ▸ | DHODH | Q02127 | 4/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5359065 | 0.91 | MALT1 (0.51) | MALT1CNR1SQORSLC6A4SLC6A3 | |
| SCHEMBL5355634 | 0.90 | CNR1 (0.61) | MALT1CNR1SQORSLC6A4SLC6A3 | |
| SCHEMBL5354246 | 0.86 | CNR1 (0.51) | MALT1CNR1KDM4ECYP2C9MAPT | |
| SCHEMBL5358197 | 0.85 | CNR1 (0.48) | MALT1CNR1SQORSLC6A4SLC6A3 | |
| SCHEMBL5364612 | 0.83 | PDK2 (0.50) | MALT1CNR1TDP1 | |
| SCHEMBL25148635 | 0.82 | TDP1 (0.46) | TDP1KDM4ECYP2C9MAPT | |
| SCHEMBL5354056 | 0.81 | CNR1 (0.64) | CNR1 | |
| SCHEMBL14408026 | 0.81 | SQOR (0.53) | MALT1CNR1SQORTDP1KDM4E | |
| SCHEMBL5363376 | 0.81 | CNR1 (0.64) | MALT1CNR1 | |
| SCHEMBL14932117 | 0.81 | POLB (0.50) | SQORTDP1KDM4EDHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7271266-B2 | Substituted 2,3-diphenyl pyridines | MERCK & CO., INC. (US) | 2007-09-18 | — | — | US | disclosed |
| US-20050182103-A1 | Substituted 2,3-diphenyl pyridines | MERCK SHARP & DOHME CORP. | 2005-08-18 | — | — | US | disclosed |
| EP-1492784-A2 | SUBSTITUTED 2,3-DIPHENYL PYRIDINES | Merck & Co., Inc. (US) | 2005-01-05 | — | — | EP | disclosed |
| WO-2003082191-A2 | SUBSTITUTED 2,3-DIPHENYL PYRIDINES | MERCK & CO., INC. (US) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182103-A1 | Substituted 2,3-diphenyl pyridines | CNR1, CNR2, MAG | MALT1 139/4885CNR1 1/4885SQOR 2338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.